SG11202009877XA - Oligonucleotide compositions and methods of use thereof - Google Patents
Oligonucleotide compositions and methods of use thereofInfo
- Publication number
- SG11202009877XA SG11202009877XA SG11202009877XA SG11202009877XA SG11202009877XA SG 11202009877X A SG11202009877X A SG 11202009877XA SG 11202009877X A SG11202009877X A SG 11202009877XA SG 11202009877X A SG11202009877X A SG 11202009877XA SG 11202009877X A SG11202009877X A SG 11202009877XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- oligonucleotide compositions
- oligonucleotide
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656949P | 2018-04-12 | 2018-04-12 | |
| US201862670709P | 2018-05-11 | 2018-05-11 | |
| US201862715684P | 2018-08-07 | 2018-08-07 | |
| US201862723375P | 2018-08-27 | 2018-08-27 | |
| US201862776432P | 2018-12-06 | 2018-12-06 | |
| PCT/US2019/027109 WO2019200185A1 (en) | 2018-04-12 | 2019-04-11 | Oligonucleotide compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009877XA true SG11202009877XA (en) | 2020-11-27 |
Family
ID=68163789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009877XA SG11202009877XA (en) | 2018-04-12 | 2019-04-11 | Oligonucleotide compositions and methods of use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220306573A1 (en) |
| EP (1) | EP3775203A4 (en) |
| JP (2) | JP2021521140A (en) |
| KR (1) | KR20210005057A (en) |
| CN (1) | CN112004928A (en) |
| AU (1) | AU2019252680B2 (en) |
| BR (1) | BR112020020670A2 (en) |
| CA (1) | CA3096667A1 (en) |
| IL (2) | IL277889B2 (en) |
| MX (1) | MX2020010687A (en) |
| SG (1) | SG11202009877XA (en) |
| WO (1) | WO2019200185A1 (en) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2872485T3 (en) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| CN104661664B (en) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | Chiral control |
| EP4137572A1 (en) | 2014-01-16 | 2023-02-22 | Wave Life Sciences Ltd. | Chiral design |
| RU2708237C2 (en) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Modified oligonucleotides and method for production thereof |
| MA43072A (en) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| MA43822A (en) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITE AND OLIGONUCLEOTIDES |
| WO2017210647A1 (en) | 2016-06-03 | 2017-12-07 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| DK3507366T3 (en) | 2016-09-01 | 2020-11-02 | Proqr Therapeutics Ii Bv | CHEMICAL MODIFIED, SINGLE STRANDED RNA-MODIFYING OLIGONUCLEOTIDES |
| MA46905A (en) | 2016-11-23 | 2019-10-02 | Wave Life Sciences Ltd | COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITES AND OLIGONUCLEOTIDES |
| CN120249271A (en) | 2017-06-02 | 2025-07-04 | 波涛生命科学有限公司 | Oligonucleotide compositions and methods of use thereof |
| WO2018223056A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| EP3642182A4 (en) | 2017-06-21 | 2020-12-09 | Wave Life Sciences Ltd. | COMPOUNDS, COMPOSITIONS AND METHODS OF SYNTHESIS |
| CN111032057A (en) | 2017-08-08 | 2020-04-17 | 波涛生命科学有限公司 | Oligonucleotide compositions and methods thereof |
| US11608355B2 (en) | 2017-09-18 | 2023-03-21 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
| JP2020537518A (en) | 2017-10-12 | 2020-12-24 | ウェーブ ライフ サイエンシーズ リミテッド | Oligonucleotide composition and its method |
| TWI844541B (en) | 2018-05-11 | 2024-06-11 | 新加坡商波濤生命科學有限公司 | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20230089442A1 (en) * | 2019-03-20 | 2023-03-23 | Pachamuthu Kandasamy | Technologies useful for oligonucleotide preparation |
| US12497615B2 (en) | 2019-04-25 | 2025-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| CN114555621B (en) | 2019-08-15 | 2025-10-28 | Ionis制药公司 | Bond-modified oligomeric compounds and uses thereof |
| JP2023506540A (en) * | 2019-12-19 | 2023-02-16 | エフ. ホフマン-ラ ロシュ エージー. | Use of SCAMP3 inhibitors to treat hepatitis B virus infection |
| BR112022012114A2 (en) * | 2019-12-19 | 2022-09-06 | Nippon Shinyaku Co Ltd | ANTISENSE NUCLEIC ACID THAT ALLOWS THE LEAP OF EXONS |
| MX2022014606A (en) * | 2020-05-22 | 2023-03-08 | Wave Life Sciences Ltd | Double stranded oligonucleotide compositions and methods relating thereto. |
| EP4153604A4 (en) * | 2020-05-22 | 2024-11-27 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREFOR |
| CN112063621B (en) * | 2020-09-02 | 2022-06-28 | 西湖大学 | Duchenne muscular dystrophy-related exon splicing enhancers, sgRNAs, gene editing tools and their applications |
| CN112430645A (en) * | 2020-12-09 | 2021-03-02 | 北京华瑞康源生物科技发展有限公司 | Relative quantitative method and kit for detecting human DMD gene copy number by multiple real-time fluorescence PCR method |
| CN118852286A (en) * | 2021-01-14 | 2024-10-29 | 施能康生物科技有限公司 | Compounds, conjugates and uses thereof |
| IL309626A (en) | 2021-06-23 | 2024-02-01 | Nippon Shinyaku Co Ltd | Combination of antisense oligomers |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2022309028A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| WO2023006985A1 (en) * | 2021-07-30 | 2023-02-02 | 4Basebio Uk Ltd | Nanoparticles and peptides for the delivery of cargos to muscle cells |
| EP4124345A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticles for muscle delivery |
| CA3227661A1 (en) * | 2021-08-05 | 2023-02-09 | Weimin Wang | 1'-alkyl modified ribose derivatives and methods of use |
| US20250154504A1 (en) | 2022-02-14 | 2025-05-15 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| AU2023227808A1 (en) * | 2022-03-02 | 2024-09-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof for exon skipping |
| CN114600803B (en) * | 2022-03-15 | 2023-05-09 | 北京协和建昊医药技术开发有限责任公司 | Zebra fish CYP3A4 metabolic enzyme inhibition model, establishing method and application |
| IL317425A (en) * | 2022-06-10 | 2025-02-01 | Camp4 Therapeutics Corp | Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas |
| JP2025524566A (en) | 2022-07-15 | 2025-07-30 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | Oligonucleotides for ADAR-mediated RNA editing and uses thereof |
| WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| EP4630553A1 (en) | 2022-12-09 | 2025-10-15 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| EP4669753A1 (en) | 2023-02-20 | 2025-12-31 | ProQR Therapeutics II B.V. | ANTISENSEE OLIGONUCLEOLITES FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| CN121039282A (en) | 2023-03-24 | 2025-11-28 | ProQR治疗上市公司Ⅱ | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2024200472A1 (en) | 2023-03-27 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| AR132964A1 (en) | 2023-06-16 | 2025-08-13 | Proqr Therapeutics Ii Bv | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| AU2024287308A1 (en) | 2023-07-13 | 2025-12-18 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025056973A2 (en) * | 2023-09-13 | 2025-03-20 | Haya Therapeutics Sa | Compositions and methods for modulating wisp2 super-enhancer-associated rna |
| WO2025072886A1 (en) * | 2023-09-28 | 2025-04-03 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2025072883A2 (en) * | 2023-09-28 | 2025-04-03 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| AU2024369609A1 (en) | 2023-10-31 | 2025-12-11 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025128799A1 (en) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| WO2025199428A1 (en) * | 2024-03-21 | 2025-09-25 | Adarx Pharmaceuticals, Inc. | Mannose receptor ligand-tropomyosin receptor b ligand conjugates for drug delivery |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852188A (en) * | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
| DK0464638T3 (en) * | 1990-07-02 | 1997-10-13 | Hoechst Ag | Oligonucleotide analogs with terminal 3-3 or 5-5 internucleotide bonds. |
| US5512668A (en) * | 1991-03-06 | 1996-04-30 | Polish Academy Of Sciences | Solid phase oligonucleotide synthesis using phospholane intermediates |
| US6242589B1 (en) * | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
| AR040996A1 (en) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
| SI1766010T1 (en) * | 2004-06-28 | 2011-06-30 | Univ Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| JP2006248949A (en) * | 2005-03-09 | 2006-09-21 | Univ Nagoya | Nucleoside derivatives, nucleotide derivatives and methods for producing them |
| ATE443072T1 (en) * | 2005-11-23 | 2009-10-15 | Roche Diagnostics Gmbh | POLYNUCLEOTIDE WITH PHOSPHATE MIMETIC |
| PL2203173T3 (en) * | 2007-10-26 | 2016-06-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2370451B1 (en) * | 2008-12-02 | 2016-11-16 | Wave Life Sciences Japan, Inc. | Method for the synthesis of phosphorus atom modified nucleic acids |
| CA2877644A1 (en) * | 2012-07-03 | 2014-01-09 | Prosensa Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
| CN104661664B (en) * | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | Chiral control |
| CA2879066C (en) * | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| PL2872485T3 (en) * | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| EP4137572A1 (en) * | 2014-01-16 | 2023-02-22 | Wave Life Sciences Ltd. | Chiral design |
| RU2708237C2 (en) * | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Modified oligonucleotides and method for production thereof |
| MA43072A (en) * | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| KR20180056766A (en) * | 2015-10-09 | 2018-05-29 | 웨이브 라이프 사이언시스 리미티드 | Nucleotide compositions and methods thereof |
| WO2017210647A1 (en) * | 2016-06-03 | 2017-12-07 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
-
2019
- 2019-04-11 SG SG11202009877XA patent/SG11202009877XA/en unknown
- 2019-04-11 EP EP19784832.8A patent/EP3775203A4/en active Pending
- 2019-04-11 BR BR112020020670-9A patent/BR112020020670A2/en unknown
- 2019-04-11 AU AU2019252680A patent/AU2019252680B2/en active Active
- 2019-04-11 KR KR1020207032342A patent/KR20210005057A/en not_active Ceased
- 2019-04-11 MX MX2020010687A patent/MX2020010687A/en unknown
- 2019-04-11 IL IL277889A patent/IL277889B2/en unknown
- 2019-04-11 US US17/046,752 patent/US20220306573A1/en active Pending
- 2019-04-11 JP JP2020555234A patent/JP2021521140A/en active Pending
- 2019-04-11 CA CA3096667A patent/CA3096667A1/en active Pending
- 2019-04-11 WO PCT/US2019/027109 patent/WO2019200185A1/en not_active Ceased
- 2019-04-11 IL IL314987A patent/IL314987A/en unknown
- 2019-04-11 CN CN201980025941.1A patent/CN112004928A/en active Pending
-
2023
- 2023-07-05 JP JP2023110962A patent/JP2023139036A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020010687A (en) | 2021-01-20 |
| IL277889A (en) | 2020-11-30 |
| KR20210005057A (en) | 2021-01-13 |
| IL277889B2 (en) | 2025-01-01 |
| US20220306573A1 (en) | 2022-09-29 |
| EP3775203A1 (en) | 2021-02-17 |
| CN112004928A (en) | 2020-11-27 |
| WO2019200185A1 (en) | 2019-10-17 |
| IL277889B1 (en) | 2024-09-01 |
| AU2019252680A1 (en) | 2020-10-22 |
| JP2021521140A (en) | 2021-08-26 |
| IL314987A (en) | 2024-10-01 |
| EP3775203A4 (en) | 2022-03-30 |
| BR112020020670A2 (en) | 2021-03-02 |
| AU2019252680B2 (en) | 2025-11-06 |
| CA3096667A1 (en) | 2019-10-17 |
| JP2023139036A (en) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277889A (en) | Oligonucleotide compositions and methods of use thereof | |
| SG11202010131QA (en) | Oligonucleotide compositions and methods of use thereof | |
| SG11202111387YA (en) | Oligonucleotide compositions and methods of use thereof | |
| SG11202111386UA (en) | Oligonucleotide compositions and methods of use thereof | |
| IL274276A (en) | Casz compositions and methods of use | |
| SG11202105626TA (en) | Oligonucleotide compositions and methods thereof | |
| IL284882A (en) | Oligonucleotide compositions and methods thereof | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| ZA202007839B (en) | Polymerases, compositions, and methods of use | |
| ZA202007838B (en) | Polymerases, compositions, and methods of use | |
| EP3965780A4 (en) | Oligonucleotide compositions and methods of use thereof | |
| SG11202001783YA (en) | Oligonucleotide compositions and methods thereof | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| IL276135A (en) | Compositions and methods of use | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| GB202105087D0 (en) | Microbial compositions and methods of use | |
| IL282533A (en) | Oligosaccharide compositions and methods of use thereof | |
| ZA202000502B (en) | Cosmetic compositions and methods of use | |
| SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| ZA201908276B (en) | Charge-tagged nucleotides and methods of use thereof | |
| IL274433A (en) | Fulvestrant formulations and methods of their use | |
| IL277801A (en) | Oxytocin compositions and methods of use | |
| IL261794A (en) | Compositions and methods of their use | |
| ZA202007107B (en) | Compositions comprising pcsk9-binding molecules and methods of use | |
| HK40079904A (en) | Oligonucleotide compositions and methods of use thereof |